

## REVIEW

# COVID-19 and pediatric pulmonology: Feedback from an expert center after the first year of the pandemic

Harriet Corvol MD, PhD<sup>1,2</sup>  | Blandine Prevost MD<sup>1,2</sup> | Guillaume Aubertin MD<sup>1,2</sup> |  
Guillaume Thouvenin MD<sup>1,2</sup> | Jessica Taytard MD, PhD<sup>1,3</sup>  |  
Nadia Nathan MD, PhD<sup>1,4</sup> 

<sup>1</sup>Service de Pneumologie Pédiatrique, Centre de Référence des Maladies Respiratoires Rares RespiRare et Centre de Ressources et de Compétences pour la Mucoviscidose, Sorbonne Université et APHP, Hôpital Armand Trousseau, Paris, France

<sup>2</sup>Centre de recherche Saint Antoine (CRSA), Paris, France

<sup>3</sup>Inserm UMRS\_S1158, Paris, France

<sup>4</sup>Inserm UMR\_S933, Paris, France

## Correspondence

Harriet Corvol, MD, PhD, Service de Pneumologie Pédiatrique, Hôpital Armand Trousseau, 26 Ave du Dr Netter, 75012 Paris, France.

Email: [harriet.corvol@aphp.fr](mailto:harriet.corvol@aphp.fr)

## Abstract

The coronavirus disease 2019 (COVID-19) outbreak has evolved with different waves corresponding to subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations. While the most severe cases have been observed in the elderly and in individuals with underlying comorbidities, severe pediatric and young adult cases have been observed, as well as post-infectious inflammatory syndromes and persistent symptoms leading to long-COVID. This manuscript describes the experience of a pediatric respiratory unit during the first year of the pandemic and reviews the corresponding literature with a special emphasis on children and young people with underlying conditions, such as immunosuppression, sickle cell disease, and cystic fibrosis.

## KEYWORDS

children, COVID-19, cystic fibrosis, immunosuppression, lung, SARS-CoV-2, sickle cell disease

## 1 | INTRODUCTION

Since its inception in December 2019, the coronavirus disease 2019 (COVID-19) outbreak has evolved with different waves, corresponding to subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations. As of August 25, 2022, at least 600 million people have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and 6.4 million individuals have died of this disease worldwide.<sup>1</sup> The most severe cases have been observed in the elderly and in individuals with underlying comorbidities, such as obesity, diabetes, hypertension, and immunosuppression. Initially thought of as being involved in the carriage and dissemination of the virus, it was quickly established during the first wave that young children were neither very contagious nor symptomatic with respect to COVID-19.<sup>2</sup> However, severe pediatric cases and post-infectious

inflammatory syndromes have been reported worldwide.<sup>3</sup> This manuscript describes the experience of a pediatric respiratory unit during the first year of the pandemic and reviews the corresponding literature with a special emphasis on children and young people with underlying conditions, such as immunosuppression, sickle cell disease, and cystic fibrosis.

## 2 | PEDIATRIC EPIDEMIOLOGY OF SARS-COV-2

At the beginning of the pandemic, Wu et al.<sup>4</sup> described the first 72,314 cases of COVID-19 in China. Children and adolescents accounted for only 2% of these cases, and no deaths were reported among children under 9 years of age. Since then, data from different

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Pediatric Pulmonology* published by Wiley Periodicals LLC.

countries have confirmed a lower initial incidence of infection in children (2%–5%) and its reduced severity in children, although severe cases and deaths have been reported in all countries, including 28 deaths in France between 2020 and 2021.<sup>1</sup>

In late 2021–early 2022, a resurgence of cases in young adults and children was observed with the delta and omicron variants in France.<sup>5–7</sup> This has caused the recrudescence of severe COVID-19 forms and hospitalizations in children, particularly in the age group of 0–9 years because of the limited vaccination coverage in this population.<sup>7–10</sup>

### 3 | CLINICAL SYMPTOMS OF COVID-19 AND RISK FACTORS FOR SEVERITY IN CHILDREN

The first pediatric COVID-19 cases were described by authors from Shanghai, China.<sup>11</sup> They reported 2135 children infected with SARS-CoV-2, with 56% boys and a median age of 7 years. The symptoms were mostly mild (51% of the cases) or moderate (38% with pneumonia and wheezing), and severe in only 6% of the cases with hypoxia and/or respiratory failure. Subsequently, it has been established that during the first wave, the infection is usually mild in children, with nonspecific clinical signs, such as cough, fever, rhinitis, headache, and digestive signs (vomiting and diarrhea).<sup>12–16</sup> Very few studies have been conducted on paucisymptomatic ambulatory patients. Nevertheless, a French study in March 2021 (before vaccination of adolescents) showed that in 2079 children presenting signs compatible with COVID-19, the polymerase chain reaction (PCR) positivity rates for SARS-CoV-2 reached 7.3%, with rates increasing with age.<sup>17</sup> In this study, apart from a loss of taste, no symptoms were predictive of COVID-19 compared with other viral infections. After the first wave, a systematic review of COVID-19 in pediatric patients evaluated 7780 pediatric cases described in 131 studies from 26 countries from December 2019 to May 2020.<sup>13</sup> They concluded that children diagnosed with COVID-19 had an overall excellent prognosis, with only 3.3% of children requiring intensive care unit (ICU) care and seven deaths. More than 35% had underlying medical conditions, with immunosuppression being the most common (30.5%), followed by respiratory (21%) and cardiovascular (13.7%) disorders.

In hospitalized children, poorly tolerated fever and fatigue are common.<sup>8,12</sup> At hospital admission, respiratory symptoms are present in approximately 50% of cases, with more than half being associated with respiratory distress.<sup>8</sup> Notably, the severity seems to be greater in infants under 1 year of age and adolescents.<sup>3</sup> During the first wave, a retrospective cohort study was conducted in Colorado, USA, in 454 children with confirmed SARS-CoV-2 infection, with the aim of evaluating the risk factors for severe COVID-19.<sup>18</sup> They showed that extremes of age (e.g., 0–3 months or >20 years), preterm birth history, comorbidities (immunosuppression, gastrointestinal condition, diabetes, and asthma), and an elevated C-reactive protein were predictors of severe disease in children. At the beginning of the

pandemic, we described hemodynamic disorders and transient neurological manifestations in young infants.<sup>19</sup> A systematic review of COVID-19 in 63 infants under 3 months of age reported moderate severity and nonspecific clinical signs; however, one-fifth of children required ICU care.<sup>20</sup> Among hospitalized adolescents, children with underlying conditions, such as asthma, obesity, or sickle cell disease are overrepresented.<sup>3,12,21–24</sup> Rare cases of pulmonary embolism associated with COVID-19 have also been reported in pediatric patients.<sup>25,26</sup>

In children, a specific hyperinflammatory syndrome with multi-organ involvement associated with COVID-19 has been described and named as a multisystemic inflammatory syndrome in children (C-MIS) or pediatric multisystemic inflammatory syndrome (PIMS).<sup>27–29</sup> PIMS occurs 2–8 weeks after a SARS-CoV-2 infection that may have been asymptomatic. It shares several similarities with Kawasaki syndrome, which has also been described as possibly secondary to viral infection. PIMS is rare but potentially serious. At the end of August 2022, 1070 cases of PIMS related to COVID-19 were reported to the French health authorities (61% boys, median age: 8 years with 32% of cases in children under 5 years of age and 72% under 11 years of age).<sup>1</sup> The main clinical symptoms of PIMS are persistent fever, systemic inflammation, gastrointestinal manifestations (abdominal pain, vomiting, and diarrhea), mucocutaneous abnormalities (skin rashes and conjunctivitis), headache, and cardiac dysfunction.<sup>27–29,30</sup> A large American study of 1080 children hospitalized for PIMS with a median age of 8 years reported 60% hospitalizations in the ICU for heart failure, coronary dysfunction, hemodynamic shock, or myocarditis, and 18 (2%) deaths.<sup>27</sup> In France, among the 1070 cases of PIMS, 725 (68%) patients were hospitalized in the ICU and one 9-year-old child died.<sup>1</sup>

Another long-term consequence of SARS-CoV-2 infection in adults and children is long-COVID.<sup>31,32</sup> The definition proposed by the WHO for this condition is that it generally occurs 3 months after the onset of SARS-CoV-2 infection, with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis.<sup>33</sup> A systematic review, which evaluated 80,071 children and adolescents from 21 studies, reported a long-COVID prevalence of 25.24%.<sup>32</sup> The most prevalent clinical manifestations were mood symptoms (16.5%), fatigue (9.7%), and sleep disorders (8.4%). Moreover, this review showed that children with a history of SARS-CoV-2 infection had a higher risk of persistent dyspnea, anosmia/ageusia, and fever. A large prospective pediatric cohort of children admitted to the hospital with confirmed COVID-19 also showed that a quarter of children had persistent symptoms (>5 months) at the time of follow-up with fatigue, sleep disturbance, and sensory problems being the most common.<sup>34</sup> In this study, almost 1 in 10 children reported multisystem impacts with at least two categories of persistent symptoms. Children in mid-childhood and adolescents (aged 6–18 years) as well as those with a history of allergic diseases (defined here as asthma, allergic rhinitis, eczema, or food allergy) were at higher risk of persistent symptoms. Although long-COVID represents a significant public health concern that may increase in the future, there are still no guidelines for its diagnosis and management in children.<sup>31,32</sup>

## 4 | FOCUS ON ATYPICAL RESPIRATORY MANIFESTATIONS OF COVID-19 IN CHILDREN AND YOUNG PEOPLE OBSERVED IN A FRENCH EXPERT CENTER DURING THE FIRST YEAR OF THE PANDEMIC

Approximately 50% of children hospitalized with COVID-19 have respiratory involvement, more than half of which is associated with respiratory distress.<sup>8,12</sup> An international study conducted between February and October 2020 in 671 children hospitalized with confirmed and symptomatic COVID-19 reported a 13.3% incidence of viral pneumonitis.<sup>9</sup> Similar to adults, some underlying conditions have been shown to be associated with a higher risk of developing severe respiratory diseases, particularly chronic respiratory diseases (asthma, cystic fibrosis [CF], and bronchopulmonary dysplasia), immunosuppression, cancer, sickle cell disease, and neurological disorders.<sup>3,12,13,21,22,26,35-38</sup> Below, we describe some of these particular cases, with a focus on patients hospitalized in our pediatric pulmonology unit during the first year of the pandemic. The description of the cases hospitalized in our unit has been approved by the local ethics committee of our institution, which waived the need for patients' consent (PED\_COVID N°20200717191204).


### 4.1 | Immunocompromised children

As of yet, there are limited published data describing the outcomes of immunocompromised children infected with SARS-CoV-2.<sup>39-42</sup> In adults, the risk of the worst COVID-19 evolution has frequently led to the postponement of anticancer therapies.<sup>42,43</sup> However, in childhood, most cancers require intensive treatment, which, if postponed, may be life-threatening. We observed an atypical respiratory course of severe SARS-CoV-2 infection in a 16-year-old adolescent, who was immunocompromised when infected with

SARS-CoV-2.<sup>44</sup> This teenager was diagnosed with bone Ewing sarcoma, which was initially treated with chemotherapy and surgical resection. Given the partial response to this treatment, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) was considered. HSCT was delayed by 2 weeks because of SARS-CoV-2 infection (isolated dysgeusia initially). Nevertheless, the patient developed an acute respiratory distress syndrome (ARDS) after the HSCT, which required ICU care with 15 days of invasive ventilation, systemic corticosteroids, convalescent plasma, and tocilizumab. Thoracic computed tomography (CT) revealed alveolar condensations in the lower lobes with diffuse confluent ground-glass opacities. At ICU discharge, the patient remained dyspneic and hypoxic. The CT scan revealed a worsening condition with lesions suggestive of post-COVID-19 organized pneumonia (Figure 1A). The treatment consisted of high doses of corticosteroids for 2 months and respiratory rehabilitation with favorable outcomes.

### 4.2 | Children with sickle cell disease

Several studies have reported that sickle cell disease is a risk factor for severe COVID-19, particularly in children.<sup>45</sup> At the beginning of the pandemic, we described the favorable outcome of a 16-year-old girl with sickle cell disease who developed acute chest syndrome (ACS) with pulmonary embolism secondary to SARS-CoV-2 infection.<sup>26</sup> This adolescent had a severe form of sickle cell disease with a history of repeated vaso-occlusive crises and bilateral ischemic retinopathy, with no history of ACS. Seven days after the onset of SARS-CoV-2 infection, which initially manifested as an isolated fever, she developed ACS with acute chest pain and ARDS. CT pulmonary angiography confirmed ACS and showed bilateral pulmonary embolism (Figure 1B1,B2). She was admitted to the ICU and required 4 days of noninvasive ventilation, 6 weeks of anticoagulation, and one pulse of intravenous tocilizumab. The patient subsequently returned to her pre-COVID clinical status.



**FIGURE 1** (A) Post-COVID organizing pneumonia in an immunocompromised adolescent. The lung computed tomography scan performed 3 weeks after the acute respiratory distress syndrome onset shows lesions of post-COVID organizing pneumonia with crazy-paving band-shaped condensations and peribroncho-vascular and scissural distortion. (B) Post-COVID acute chest syndrome and pulmonary embolism in a child with sickle cell disease: (1) The lung computed tomography scan performed at COVID-19 onset shows acute chest syndrome secondary to COVID-19 with round subpleural consolidation with a "halo sign" of ground-glass opacities (black arrows) and interlobular septal thickening (black arrowhead) on the right side, and lobar consolidation (lingula and lower lobe) with adjacent ground-glass opacities on the left side. (2) The mediastinal window shows bilateral pulmonary embolism (white arrows) and left pleural effusion (white arrowhead).

### 4.3 | Young people with cystic fibrosis (pwCF)

Since the first wave of COVID-19 in France in March 2020, all 47 CF centers (which follow approximately 7500 pwCF<sup>46</sup>) have been collaborating to conduct a prospective observational study to describe the clinical manifestations of SARS-CoV-2 infection in French pwCF. During the first wave (March–June 2020), 31 French pwCFs were reported to be infected with SARS-CoV-2, 12 of whom were post-lung transplantation.<sup>47</sup> The majority of patients had CF-related diabetes (61%) and moderate respiratory disease in the year before infection (65% had a pre-infection FEV<sub>1</sub> > 70%). More recently, this study was updated with a description of 223 French pwCFs diagnosed with COVID-19 during the first year of the pandemic.<sup>48</sup> It showed a higher risk of infection in adults and post-transplant individuals. Using objective clinical markers (e.g., respiratory failure and/or death), this study highlighted that the risk factors for severity included low lung function and diabetes in non-transplanted individuals and post-transplant status. An international registry was also set up at the beginning of the pandemic, which described 181 pwCFs (32 post-transplant) with COVID-19 during the first wave.<sup>49</sup> The impact of SARS-CoV-2 infection appeared to be similar in pwCF and the general population, with 11 patients admitted to the ICU (7 post-transplant) and 7 deaths (3 post-transplant).

This international consortium also detailed more precisely the 105 pediatric international COVID-19 cases: 54% were males, with a median age of 10 years, and a median FEV<sub>1</sub> of 94%.<sup>50</sup> Only 24 children were hospitalized, 6 children required additional oxygen therapy, and 2 children required noninvasive ventilation. The hospitalized children had significantly worse lung function before infection. One child died 6 weeks after testing positive for SARS-CoV-2 because of respiratory worsening that was not attributed to COVID-19. We observed similar features in the pediatric CF center host of our pediatric pulmonology unit. Most children with CF who were diagnosed as infected by SARS-CoV-2 during the first COVID wave remained asymptomatic; the diagnosis was confirmed by a systematic assessment of SARS-CoV-2 serology or by SARS-CoV-2 RT-PCR performed in case of contact.<sup>10</sup>

It is still difficult to estimate the true susceptibility of pwCF to SARS-CoV-2 infection. Indeed, they are used in barrier gestures, such as wearing masks, frequent hand washing, and social distancing, to limit exposure and avoid infection. Epidemiological studies performed during the first wave of the pandemic have shown that the incidence remained low, with a short-term evolution that appeared relatively favorable in non-transplanted pwCF, but more severe in post-transplant patients.

## 5 | RADIOLOGICAL SIGNS OF COVID-19 IN CHILDREN

When a child is hospitalized for respiratory distress associated with COVID-19, chest radiography should be performed. If the chest radiograph is observed to be abnormal with the presence of serious

respiratory clinical signs and/or underlining conditions known to lead to severe COVID-19 (sickle cell disease, obesity, etc.), CT pulmonary angiography should be performed to identify COVID-19 complications, such as ARDS and pulmonary embolism. A meta-analysis of the CT scans of 1747 children with COVID-19 found 63.2% of abnormalities on chest CT, including 39.5% of ground-glass opacities and 65.1% of bilateral lung lesions, but also rare abnormalities, such as pulmonary nodules (25.7%), patchy shadows (36.8%), halo signs (24.8%), consolidation (24.1%), air bronchogram signs (11.2%), cord-like shadows (9.7%), crazy-paving pattern (6.1%), and pleural effusion (9.1%).<sup>51</sup> Compared to adults, ground-glass opacities are less frequently reported, as is the bilaterality of lesions.<sup>52</sup> It is also important to note that pulmonary embolism must be considered in adolescents, especially in cases of thromboembolic risk factors or suggestive biological markers.<sup>25</sup> In PIMS, respiratory involvement is relatively rare or mild (mainly bronchial thickening), whereas extra-respiratory radiological involvement is more common with cardiomegaly, mesenteric inflammation, hepatosplenomegaly, periportal edema, ascites, or thickening of the digestive walls.<sup>30,53</sup>

## 6 | MANAGEMENT OF COVID-19 IN CHILDREN

The management of SARS-CoV-2 infections in children is mostly based on adult recommendations and has evolved through various waves of the pandemic. Recent recommendations have been developed by the National Institutes of Health.<sup>54</sup> Most children require only symptomatic treatment, particularly fever control with acetaminophen. In cases of severe respiratory diseases, treatment with dexamethasone is discussed in a manner similar to that in adults. Therefore, systematic antibiotic therapy was not recommended. Other therapies, such as paxlovid, remdesivir, tocilizumab, convalescent plasma, and monoclonal antibodies, have been shown to be effective.<sup>54</sup>

Prophylactic management is based on barrier gestures and the SARS-CoV-2 vaccine. Indeed, vaccination is recommended in children older than 5 years, for whom the BNT162b2 COVID-19 vaccine has been deemed safe, immunogenic, and effective.<sup>55</sup> However, the vaccination rates in children remain limited in most countries, making it difficult to evaluate their effectiveness on a large scale.<sup>56</sup>

## 7 | CONCLUSION

The knowledge of COVID-19 in children is evolving through consecutive waves of different SARS-CoV-2 variants. These variants have caused variable pathogenicity and transmissibility, with an increase in incidence in children in the coming months. Vaccination of children older than 5 years for whom the BNT162b2 COVID-19 vaccine has been shown to be safe and effective is also likely to modify the epidemiology and the immediate and post-infectious manifestations of COVID-19 in children.

## AUTHOR CONTRIBUTIONS

Harriet Corvol, Blandine Prevost, Jessica Taytard, and Nadia Nathan were involved in the writing of the original draft, reviewing, and editing the manuscript. Guillaume Aubertin and Guillaume Thouvenin were involved in critically reviewing and editing the manuscript.

## ACKNOWLEDGMENTS

The authors would like to thank the medical and nursing staff of the Pediatric Pulmonology Department at Trousseau Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

## ORCID

Harriet Corvol  <https://orcid.org/0000-0002-7026-7523>

Jessica Taytard  <http://orcid.org/0000-0002-7552-3880>

Nadia Nathan  <http://orcid.org/0000-0001-5149-7975>

## REFERENCES

1. Santé publique France. *Chiffres clés et évolution de la COVID-19 en France et dans le Monde*. 2022. <https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/>
2. Cohen R, Jung C, Ouldali N, et al. Assessment of SARS-CoV-2 infection by reverse transcription-PCR and serology in the Paris area: a cross-sectional study. *BMJ Paediatr Open*. 2020;4(1):e000887.
3. Harwood R, Yan H, Talawila Da Camara N, et al. Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: a systematic review and individual patient meta-analysis. *EclinicalMedicine*. 2022;44:101287.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239-1242.
5. Nathan N, Prevost B, Lambert S, Schnuriger A, Corvol H. Severe acute respiratory syndrome coronavirus 2 variant Delta infects all 6 siblings but spares comirnaty (BNT162b2, BioNTech/Pfizer)-vaccinated parents. *J Infect Dis*. 2021;224(11):1984-1986.
6. Taytard J, Prevost B, Corvol H. More on BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. *N Engl J Med*. 2022;386(12):1191-1193.
7. Taytard J, Prevost B, Schnuriger A, et al. SARS-CoV-2 B.1.1.529 (Omicron) variant causes an unprecedented surge in children hospitalizations and distinct clinical presentation compared to the SARS-CoV-2 B.1.617.2 (Delta) variant. *Front Pediatr*. 2022;10:932170.
8. Abdukahil SA, Abe R, Abel L, et al. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. *Infection*. 2021;49(5):889-905.
9. Bourgeois FT, Gutiérrez-Sacristán A, Keller MS, et al. International analysis of electronic health records of children and youth hospitalized with COVID-19 infection in 6 countries. *JAMA Network Open*. 2021;4(6):e2112596.
10. Thouvenin G, Prevost B, Corvol H. The omicron wave modifies the COVID-19 paradigm in children with cystic fibrosis. *J Infect Dis*. 2022;jiac328. doi:10.1093/infdis/jiac328
11. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. *Pediatrics*. 2020;145(6):e20200702.
12. Nathan N, Prevost B, Sileo C, et al. The wide spectrum of COVID-19 clinical presentation in children. *J Clin Med*. 2020;9(9):2950.
13. Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review. *EclinicalMedicine*. 2020;24:100433.
14. Kalyanaraman M, Anderson MR. COVID-19 in children. *Pediatr Clin North Am*. 2022;69(3):547-571.
15. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141-154.
16. Wang JG, Zhong ZJ, Mo YF, Wang LC, Chen R. Epidemiological features of coronavirus disease 2019 in children: a meta-analysis. *Eur Rev Med Pharmacol Sci*. 2021;25(2):1146-1157.
17. Eskander E, Levy C, Batard C, et al. Infection SARS CoV-2 en ambulatoire chez l'enfant. *Perfectionnement en Pédiatrie*. 2021;4(2, Suppl 1):E3-E4.
18. Graff K, Smith C, Silveira L, et al. Risk factors for severe COVID-19 in children. *Pediatr Infect Dis J*. 2021;40(4):e137-e145.
19. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. *Lancet*. 2020;395(10235):1481.
20. Mark EG, Golden WC, Gilmore MM, et al. Community-onset severe acute respiratory syndrome coronavirus 2 infection in young infants: a systematic review. *J Pediatr*. 2021;228:94-100.e3.
21. Ouldali N, Yang DD, Madhi F, et al. Factors associated with severe SARS-CoV-2 infection. *Pediatrics*. 2021;147(3):e2020023432.
22. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. *Pediatr Infect Dis J*. 2020;39(5):355-368.
23. Woodruff RC, Campbell AP, Taylor CA, et al. Risk factors for severe COVID-19 in children. *Pediatrics*. 2022;149(1):e2021053418.
24. Prevost B, Retbi A, Binder-Foucard F, et al. Risk factors for admission to the pediatric critical care unit among children hospitalized with COVID-19 in France. *Front Pediatr*. 2022;10:975826.
25. Chima M, Williams D, Thomas NJ, Krawiec C. COVID-19-Associated pulmonary embolism in pediatric patients. *Hosp Pediatr*. 2021;11(6):e90-e94.
26. Odièvre MH, de Marcellus C, Ducou Le Pointe H, et al. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome. *Am J Hematol*. 2020;95(8):E192-E194.
27. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. *Lancet Child Adolesc Health*. 2021;5(5):323-331.
28. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health*. 2020;4(9):669-677.
29. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. *BMJ*. 2020;369:m2094.
30. Blondiaux E, Parisot P, Redheuil A, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. *Radiology*. 2020;297(3):E283-E288.
31. Izquierdo-Pujol J, Moron-Lopez S, Dalmau J, et al. Post COVID-19 condition in children and adolescents: an emerging problem. *Front Pediatr*. 2022;10:894204.

32. Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. *Sci Rep.* 2022;12(1):9950.
33. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis.* 2022;22(4):e102-e107.
34. Osmanov IM, Spiridonova E, Bobkova P, et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. *Eur Respir J.* 2022;59(2):2101341.
35. Moeller A, Thanikkel L, Duijts L, et al. COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres. *ERJ Open Res.* 2020;6(4):00409-2020.
36. Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatr.* 2020;174(9):868-873.
37. González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A, et al. Pediatric critical care and COVID-19. *Pediatrics.* 2020;146(3):e20201766.
38. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2-associated deaths among persons aged <21 years—United States, February 12–July 31, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(37):1324-1329.
39. Kotecha RS. Challenges posed by COVID-19 to children with cancer. *Lancet Oncol.* 2020;21(5):e235.
40. Zamperlini-Netto G, Fernandes JF, Garcia JL, et al. COVID-19 after hematopoietic stem cell transplantation: report of two children. *Bone Marrow Transplant.* 2021;56(3):713-715.
41. Feldman AG, Danziger-Isakov LA. The impact of COVID-19 on the pediatric solid organ transplant population. *Semin Pediatr Surg.* 2022;31(3):151178.
42. Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). *Leukemia.* 2022;36(6):1467-1480.
43. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.* 2020;21(3):335-337.
44. Corvol H, Alimi A, Prevost B, et al. Atypical severe organizing pneumonia following coronavirus disease 2019 in an immunocompromised teenager. *Clin Infect Dis.* 2022;74(5):938-939.
45. Hoogenboom WS, Alamuri TT, McMahon DM, et al. Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: a critical appraisal of the literature. *Blood Rev.* 2022;53:100911.
46. Vaincre-la-Mucoviscidose. Registre Français de la mucoviscidose - Bilan des données 2018. 2020.
47. Corvol H, de Miranda S, Lemonnier L, et al. First wave of COVID-19 in French patients with cystic fibrosis. *J Clin Med.* 2020;9(11):3624.
48. Corvol H, de Miranda S, Dehillotte C, et al. Cumulative incidence and risk factors for severe COVID-19 in French people with cystic fibrosis. *Clin Infect Dis.* 2022:ciac333. doi:10.1093/cid/ciac333
49. McClenaghan E, Cosgriff R, Brownlee K, et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. *J Cyst Fibros.* 2020;19(6):868-871.
50. Bain R, Cosgriff R, Zampoli M, et al. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study. *J Cyst Fibros.* 2021;20(1):25-30.
51. Wang J, Mo Y, Su Y, et al. Computed tomography features of COVID-19 in children: A systematic review and meta-analysis. *Medicine.* 2021;100(38):e22571.
52. Waller JV, Lin KK, Diaz MJ, et al. CT presentations of adult and pediatric SARS-CoV-2 patients: a review of early COVID-19 data. *Radiologia (Eng Ed).* 2021;63(6):495-504.
53. Ucan B, Kaynak Sahap S, Cinar HG, et al. Multisystem inflammatory syndrome in children associated with SARS-CoV-2: extracardiac radiological findings. *Br J Radiol.* 2022;95(1129):20210570.
54. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. <https://www.covid19treatmentguidelines.nih.gov/>
55. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. *N Engl J Med.* 2022;386(1):35-46.
56. Gerber JS, Offit PA. COVID-19 vaccines for children. *Science.* 2021;374(6570):913.

**How to cite this article:** Corvol H, Prevost B, Aubertin G, Thouvenin G, Taytard J, Nathan N. COVID-19 and pediatric pulmonology: Feedback from an expert center after the first year of the pandemic. *Pediatric Pulmonology.* 2023;58: 392-397. doi:10.1002/ppul.26235